186 related articles for article (PubMed ID: 18547948)
1. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Serebruany VL; Alberts MJ; Hanley DF
Cerebrovasc Dis; 2008; 26(1):93-4. PubMed ID: 18547948
[No Abstract] [Full Text] [Related]
2. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
3. Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
Serebruany VL
Cardiology; 2008; 111(4):265-7. PubMed ID: 18434736
[No Abstract] [Full Text] [Related]
4. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Lazar LD; Lincoff AM
Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel: Clinical development and therapeutic application.
Guerra DR; Tcheng JE
Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Mariani M; Mariani G; De Servi S
Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
[TBL] [Abstract][Full Text] [Related]
8. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Wiviott SD
Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
[TBL] [Abstract][Full Text] [Related]
9. Prasugrel: a critical comparison with clopidogrel.
Reinhart KM; White CM; Baker WL
Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804
[TBL] [Abstract][Full Text] [Related]
10. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
[TBL] [Abstract][Full Text] [Related]
11. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
12. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
Baker WL; White CM
Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
14. Thienopyridine antiplatelet agents: focus on prasugrel.
Freeman MK
Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel development - claims and achievements.
Serebruany V; Shalito I; Kopyleva O
Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
[TBL] [Abstract][Full Text] [Related]
17. Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
Rodriguez L; Conde D; Lalor N; Elissamburu P; Trivi M
Am J Emerg Med; 2013 Aug; 31(8):1287. PubMed ID: 23769852
[No Abstract] [Full Text] [Related]
18. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Hobson A; Curzen N
Thromb Haemost; 2009 Jan; 101(1):23-30. PubMed ID: 19132185
[No Abstract] [Full Text] [Related]
19. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Capranzano P; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
[TBL] [Abstract][Full Text] [Related]
20. Delays of event adjudication in the TRITON trial.
Serebruany VL
Cardiology; 2010; 115(3):217-20. PubMed ID: 20234133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
